Shire PLC (LON:SHP) had its price objective upped by Berenberg Bank from GBX 5,900 ($77.60) to GBX 6,000 ($78.92) in a research note published on Monday morning. Berenberg Bank currently has a buy rating on the biopharmaceutical company’s stock.

A number of other research analysts have also commented on the stock. Goldman Sachs Group, Inc. (The) reiterated a conviction-buy rating on shares of Shire PLC in a research note on Tuesday, October 17th. Deutsche Bank AG reiterated a buy rating and set a GBX 6,000 ($78.92) price objective on shares of Shire PLC in a research note on Friday, August 4th. Morgan Stanley lowered their price objective on shares of Shire PLC from GBX 5,800 ($76.29) to GBX 5,700 ($74.97) and set an overweight rating on the stock in a research note on Thursday, October 12th. Shore Capital reiterated a buy rating on shares of Shire PLC in a research note on Thursday, October 26th. Finally, Liberum Capital reiterated a hold rating and set a GBX 4,900 ($64.45) price objective on shares of Shire PLC in a research note on Tuesday, July 18th. Four equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. Shire PLC currently has an average rating of Buy and a consensus target price of GBX 5,358.82 ($70.48).

Shire PLC (SHP) opened at GBX 3,547 ($46.65) on Monday. Shire PLC has a 12 month low of GBX 3,435.50 ($45.19) and a 12 month high of GBX 5,186 ($68.21).

ILLEGAL ACTIVITY NOTICE: “Shire PLC (SHP) Price Target Increased to GBX 6,000 by Analysts at Berenberg Bank” was published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another publication, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.watchlistnews.com/shire-plc-shp-price-target-increased-to-gbx-6000-by-analysts-at-berenberg-bank/1691799.html.

In other news, insider Anne Minto acquired 190 shares of the stock in a transaction on Friday, September 29th. The shares were purchased at an average cost of GBX 3,785 ($49.78) per share, for a total transaction of £7,191.50 ($9,458.77). Also, insider Flemming Ornskov acquired 8,400 shares of the stock in a transaction on Tuesday, August 22nd. The shares were purchased at an average price of GBX 3,665 ($48.20) per share, for a total transaction of £307,860 ($404,919.11).

About Shire PLC

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Analyst Recommendations for Shire PLC (LON:SHP)

Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.